CSI Market
Sign In | Register

Hepion Pharmaceuticals Inc (HEPA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access HEPA Annual Cash Flow →
Reviewing cash flow figures over time highlights how Hepion Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-2.06
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.05
Research And Development Expense Cost Of License-
Fair Value Adjustment Of Warrants And Contingent Consideration-
Change In Fair Value Of Debt-
Stock Issued During Period Value Issued For Milestone Payments-
Derecognition Of Warrants Issued-
Fair Value Of Warrants Issued-
Warrants Issued To Placement Agent-
Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability-
Increase Decrease In Right Of Use Asset-
Increase Decrease In Operating Lease Right Of Use Asset0.09
Warrant Inducement Expense-0.09
Write Off Related Party Note Receivable-
Goodwill And Intangible Asset Impairment-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.25
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.94
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.89
Discontinued operations0.00
Net Cash flow from Operating Activities-0.82
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Payments to Fund Long-term Loans to Related Parties0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.67
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Stock Issuance Costs Private Placement-
Increase In Notes Payable Related Parties Current-
Decrease In Notes Payable Related Parties Current-
Proceeds From Issuance Of Common Stock And Warrants-
Issuance Of Common Stock Via Stock Option Exxercise-
Payments Made For Capital Lease-
Proceeds From Issuance Of Short Term Debt And Common Stock-
Proceeds From Issuance Of Debt And Issuance Of Private Placement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.82
Total Cash Flow-0.20
4 historic quarters locked

Sign in to unlock the full Hepion Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Hepion Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037562

Figures are derived from filed reports and may be restated. Historical data is subject to revision.